Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.

被引：4
|
作者：
Loibl, Sibylle
Majewski, Ian
Guarneri, Valentina
Nekljudova, Valentina
Holmes, Eileen McCormick
Bria, Emilio
Denkert, Carsten
Eidtmann, Holger
Sotiriou, Christos
Loi, Sherene
Andre, Fabrice
Untch, Michael
Conte, Pier Franco
Piccart-Gebhart, Martine J.
Von Minckwitz, Gunter
Baselga, Jose
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Univ Padua, IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Frontier Sci Scotland, Kingussie, Inverness, Scotland
[5] Univ Verona, I-37100 Verona, Italy
[6] Charite, Inst Pathol, D-13353 Berlin, Germany
[7] Univ Kiel, Kiel, Germany
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
[9] Peter MacCallum Canc Ctr, East Melbourne, Australia
[10] Inst Gustave Roussy, Villejuif, France
[11] Helios Klinikum Berlin Buch, Berlin, Germany
[12] IOV IRCCS, Inst Oncol Veneto, Padua, MO, Italy
[13] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PIK3CA mutation status, progression and survival in advanced HR +/HER2-breast cancer: a meta-analysis of published clinical trials
    Fillbrunn, Mirko
    Signorovitch, James
    Andre, Fabrice
    Wang, Iris
    Lorenzo, Ines
    Ridolfi, Antonia
    Park, Jinhee
    Dua, Akanksha
    Rugo, Hope S.
    BMC CANCER, 2022, 22 (01)
  • [32] Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA-BRCA data
    Chen, Haizhu
    Hu, Xingbin
    Wang, Daquan
    Wang, Ying
    Yu, Yunfang
    Yao, Herui
    TRANSLATIONAL ONCOLOGY, 2023, 37
  • [33] SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
    Oliveira, M.
    Villagrasa, P.
    Ciruelos, E. M.
    Gavila, J.
    Cortegoso, A.
    Henao, F.
    Vega, E.
    Salvador, J.
    Quiroga, V.
    Estevez, L. G.
    Morales, S.
    Tolosa, P.
    Salvador, F.
    Gonzalez, X.
    Saura, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S389 - S389
  • [34] Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)
    Oliveira, Mafalda
    Villagrasa, Patricia
    Ciruelos, Eva
    Gavila, Joaquin
    Cortegoso, Alexandra
    Henao, Fernando
    Vega, Estela
    Bofill, Javier S.
    Quiroga, Vanesa
    Garcia-Estevez, Laura
    Morales, Serafin
    Tolosa, Pablo
    Celiz, Pamela
    Farre, Xavier Gonzalez
    Saura, Cristina
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Prognostic value of PIK3CA mutations in HER2-positive early stage breast cancer: A French cohort study.
    Coussy, Florence
    Lehmann-Che, Jacqueline
    Sanna, Alice
    Giacchetti, Sylvie
    Bertheau, Philippe
    Cuvier, Caroline
    Lalloum, Marjorie
    Poirot, Brigitte
    de Roquancourt, Anne
    Bouhidel, Fatiha
    Rigon, Matthieu Resche
    Espie, Marc
    Teixeira, Luis
    de Cremoux, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials
    Jank, P.
    Loibl, S.
    Fasching, P. A.
    Karn, T.
    Marme, F.
    Mueller, V.
    Schem, C.
    Stickeler, E.
    Lederer, B.
    Denkert, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] PIK3CA mutation analysis in circulating tumor cells of patients with hormone receptor positive metastatic breast cancer
    Marino, Elena
    Mauro, Cristian
    Belloni, Elena
    Picozzi, Marco
    Favalli, Valentina
    Cassatella, Maria Cristina
    Zorzino, Laura
    Giaco, Luciano
    Pelicci, Pier Giuseppe
    Barberis, Massimo
    Sandri, Maria Teresa
    Bernard, Loris
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 39
  • [38] Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights
    Araya, Carla
    Mino, Barbara
    Le Cerf, Patricio
    Gaete, Fancy
    Armisen, Ricardo
    Carvajal-Hausdorf, Daniel E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [39] Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.
    Jiang, Zefei
    Xu, Binghe
    Yan, Min
    Ouyang, Quchang
    Hu, Xi-Chun
    Li, Wei
    Feng, Ji Feng
    Zhang, Qingyuan
    Tong, Zhongsheng
    Yan, Ping
    Zhu, Xiaoyu
    Rong, Shangyi
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis
    Ibrahim, Ezzeldin M.
    Kazkaz, Ghieth A.
    Al-Mansour, Mubarak M.
    Al-Foheidi, Meteb E.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 463 - 476
12345